Has Steven Rivas, MD received payments from drug or device companies?

Yes. Drug and device makers reported $10,377 in general payments to Steven Rivas, MD across 154 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Steven Rivas, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Steven Rivas, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Steven Rivas, MD

Interventional Cardiology · Fajardo, PRNPI 1164550307

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,399 of the $10,377 with a category attached, or 61.7%. 14 manufacturers reported payments, led by Medtronic at 40.9% of the total. Reporting peaked in 2019 at $6,460 and has fallen 93.0% since, to $453 in 2025. That places this record below the midpoint for interventional cardiology clinicians in PR, where the typical reported total is $12,032.

$10,377in general payments, 2019–2025

Across 154 payments — averaging $67.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$4K
Abbott$3K
Boston Scientific$840
Johnson & Johnson$631
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$454
PBG Puerto Rico LLC$393
plus $1K from 8 others

What the payments were for

Travel & lodging$3,97238%
Food & beverage$6,39962%
Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic(2 entities)	38	$4,244
Abbott	15	$2,798
Boston Scientific	12	$840
Johnson & Johnson	25	$631
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	17	$454
PBG Puerto Rico LLC	18	$393
Amgen	6	$322
AstraZeneca	11	$218
E.r. Squibb & Sons, L.L.C.	5	$182
Bayer	1	$125
Boehringer Ingelheim	2	$63
Cordis US CORP.	1	$58
Merck	2	$37
Pfizer Pharmaceuticals LLC	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,377 in reported general payments places this provider in the 45th percentile of 39 interventional cardiology providers in Puerto Rico.

See all interventional cardiology providers in Puerto Rico →

Medicare billing

Part B allowed, 2024

$10,407

Medicare patients

Services billed

147

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	90	$72,704
EntrestoSacubitril/Valsartan	82	$71,188
XareltoRivaroxaban	62	$61,741
BrilintaTicagrelor	40	$31,362
Repatha SureclickEvolocumab	35	$25,802
FarxigaDapagliflozin Propanediol	27	$25,746
JardianceEmpagliflozin	16	$15,628
Candesartan Cilexetil	61	$7,535
Metoprolol Succinate	215	$4,398
Doxazosin Mesylate	209	$4,344
SynthroidLevothyroxine Sodium	33	$3,519
Irbesartan	70	$2,213
Atorvastatin Calcium	150	$2,204
ClopidogrelClopidogrel Bisulfate	119	$1,812
Isosorbide Mononitrate ErIsosorbide Mononitrate	82	$1,759

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Johnson & JohnsonXarelto	$631	$61,74162 claims
AstraZenecaBrilinta, Farxiga	$218	$57,10767 claims
Boehringer IngelheimJardiance	$63	$15,62816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 39 interventional cardiology providers in Puerto Rico.

Other interventional cardiology in Fajardo

See the full list for Puerto Rico →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →